As of June 30, the company had cash and cash equivalents of approximately $33.4M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio Completes Phase I/II Trial for INKmune™
- INmune Bio options imply 16.2% move in share price post-earnings
- Largest borrow rate increases among liquid names
- INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints
- INmune Bio options imply 14.9% move in share price post-earnings